PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
复制标题
DOI：
10.1182/blood-2016-02-698936
复制
发表时间：
2016-09-08
期刊：
影响因子：
20.3
通讯作者：
Ohshima, Koichi
中科院分区：
文献类型：
--
作者：
Miyoshi, Hiroaki;Kiyasu, Junichi;Ohshima, Koichi
程序性细胞死亡配体1（PD-L1）在淋巴恶性肿瘤的肿瘤和肿瘤浸润性非恶性细胞上表达。程序性细胞死亡1（PD-1）/PD-L1通路抑制宿主抗肿瘤反应，尽管对PD-1/PD-L1表达在肿瘤微环境中的意义知之甚少。为了研究PD-L1表达对成人T细胞白血病/淋巴瘤（ATLL）的临床病理学影响，我们对135例ATLL活检样本进行了PD-L1免疫染色。我们观察到两个主要群体：1例在淋巴瘤细胞中有明确的PD-L1表达（nPD-L1（+），7.4%的患者），另1例在淋巴瘤细胞中显示最小表达（nPD-L1（-），92.6%）。在nPD-L1（-）组中，出现了2个亚组：第一个亚组在肿瘤微环境的非恶性基质细胞中显示出丰富的PD-L1表达（miPD-L1（+），58.5%），第二个亚组在任何细胞中均不表达PD-L1（PD-L1（-），34.1%）。nPD-L1（+）ATLL（中位生存时间[MST] 7.5个月，95% CI [0.4-22.3]）的总生存期（OS）低于nPD-L1（-）ATLL（MST 14.5个月，95% CI [10.1-20.0]）（P =.0085）。在nPD-L1（-）ATLL中，miPD-L1（+）ATLL（MST 18.6个月，95% CI [11.0-38.5]）的OS优于PD-L1（）ATLL（MST 10.2个月，95% CI [8.0-14.7]）（P =.0029）。在多变量分析中，nPD-L1和miPD-L1的表达维持了OS的预后价值（分别为P = 0.0322和P = 0.0014）。这是第一份描述ATLL中PD-L1表达的临床病理特征和结局的报告。更详细的研究将揭示PD-L1表达在ATLL中的临床和生物学意义。
Programmed cell death ligand 1 (PD-L1) is expressed on both tumor and tumor-infiltrating nonmalignant cells in lymphoid malignancies. The programmed cell death 1 (PD-1)/PD-L1 pathway suppresses host antitumor responses, although little is known about the significance of PD-1/PD-L1 expression in the tumor microenvironment. To investigate the clinicopathological impact of PD-L1 expression in adult T-cell leukemia/lymphoma (ATLL), we performed PD-L1 immunostaining in 135 ATLL biopsy samples. We observed 2 main groups: 1 had clear PD-L1 expression in lymphoma cells (nPD-L1(+), 7.4% of patients), and the other showed minimal expression in lymphoma cells (nPD-L1(-), 92.6%). Within the nPD-L1(-) group, 2 subsets emerged: the first displayed abundant PD-L1 expression in nonmalignant stromal cells of the tumor microenvironment (miPD-L1(+), 58.5%) and the second group did not express PD-L1 in any cell (PD-L1(-), 34.1%). nPD-L1(+) ATLL (median survival time [MST] 7.5 months, 95% CI [0.4-22.3]) had inferior overall survival (OS) compared with nPD-L1(-) ATLL (MST 14.5 months, 95% CI [10.1-20.0]) (P =.0085). Among nPD-L1(-) ATLL, miPD-L1(+) ATLL (MST 18.6 months, 95% CI [11.0-38.5]) showed superior OS compared with PD-L1() ATLL (MST 10.2 months, 95% CI [8.0-14.7]) (P =.0029). The expression of nPD-L1 and miPD-L1 maintained prognostic value for OS in multivariate analysis (P =.0322 and P =.0014, respectively). This is the first report describing the clinicopathological features and outcomes of PD-L1 expression in ATLL. More detailed studies will disclose clinical and biological significance of PD-L1 expression in ATLL.